FDA OKs drug to treat bleeding disorder

Apr 30, 2007

The U.S. Food and Drug Administration has approved Humate-P for the treatment of a specific bleeding disorder called von Willebrand disease.

Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) was approved for prevention of excessive bleeding during and after surgery in certain patients with mild to severe von Willebrand disease, or vWD. The disease is the most common inherited bleeding disorder, affecting about 1 percent of the U.S. population.

Humate-P is the second biological product to be approved for the management of surgery and invasive procedures in patients with vWD in whom the medication desmopressin might not work. The first biological product, Aphanate, was approved by FDA in February. However, FDA officials said Humate-P is the first product specifically for patients with severe vWD who are undergoing major surgery.

Humate-P is manufactured by CSL Behring GmbH, located in Marburg, Germany.

Copyright 2007 by United Press International

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Nike krypton laser achieves spot in Guinness World Records

just added

A set of experiments conducted on the Nike krypton fluoride (KrF) laser at the U.S. Naval Research Laboratory (NRL) nearly five years ago has, at long last, earned the coveted Guinness World Records title for achieving "Highest ...

Narcissistic CEOs and financial performance

just added

Narcissism, considered by some as the "dark side of the executive personality," may actually be a good thing when it comes to certain financial measures, with companies led by narcissistic CEOs outperforming those helmed ...

Election surprises tend to erode trust in government

4 minutes ago

When asked who is going to win an election, people tend to predict their own candidate will come out on top. When that doesn't happen, according to a new study from the University of Georgia, these "surprised losers" often ...

Fires in Central Africa During July 2014

10 minutes ago

Hundreds of fires covered central Africa in mid-July 2014, as the annual fire season continues across the region. Multiple red hotspots, which indicate areas of increased temperatures, are heavily sprinkled ...

Recommended for you

Determine patient preferences by means of conjoint analysis

23 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0